wave life sciences - WVE
WVE
Close Chg Chg %
6.39 -0.04 -0.63%
Closed Market
6.35
-0.04 (0.63%)
Volume: 1.10M
Last Updated:
May 14, 2025, 4:00 PM EDT
Company Overview: wave life sciences - WVE
WVE Key Data
| Open $6.40 | Day Range 6.23 - 6.62 |
| 52 Week Range 4.25 - 16.74 | Market Cap $984.92M |
| Shares Outstanding 154.13M | Public Float 123.05M |
| Beta -0.92 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.83 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.72M |
WVE Performance
| 1 Week | -2.96% | ||
| 1 Month | 7.94% | ||
| 3 Months | -40.89% | ||
| 1 Year | 2.08% | ||
| 5 Years | -38.44% |
WVE Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
13
Full Ratings ➔
About wave life sciences - WVE
Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.
WVE At a Glance
Wave Life Sciences Ltd.
Marina One East Tower
Singapore, Central Singapore 018936
| Phone | 65-6236-3388 | Revenue | 108.30M | |
| Industry | Biotechnology | Net Income | -97,008,000.00 | |
| Sector | Health Technology | Employees | 288 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
WVE Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 15.794 |
| Price to Book Ratio | 9.035 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -14.17 |
| Enterprise Value to Sales | 13.312 |
| Total Debt to Enterprise Value | 0.018 |
WVE Efficiency
| Revenue/Employee | 376,048.611 |
| Income Per Employee | -336,833.333 |
| Receivables Turnover | 76.162 |
| Total Asset Turnover | 0.345 |
WVE Liquidity
| Current Ratio | 2.888 |
| Quick Ratio | 2.888 |
| Cash Ratio | 2.723 |
WVE Profitability
| Gross Margin | 92.001 |
| Operating Margin | -101.94 |
| Pretax Margin | -89.572 |
| Net Margin | -89.572 |
| Return on Assets | -30.936 |
| Return on Equity | -73.243 |
| Return on Total Capital | -39.955 |
| Return on Invested Capital | -62.979 |
WVE Capital Structure
| Total Debt to Total Equity | 11.686 |
| Total Debt to Total Capital | 10.463 |
| Total Debt to Total Assets | 7.213 |
| Long-Term Debt to Equity | 8.48 |
| Long-Term Debt to Total Capital | 7.317 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Wave Life Sciences - WVE
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 40.96M | 3.65M | 113.31M | 108.30M | |
Sales Growth
| +104.03% | -91.09% | +3,005.10% | -4.42% | |
Cost of Goods Sold (COGS) incl D&A
| - | 10.11M | 9.21M | 8.66M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 9.84M | 10.11M | 9.21M | 8.66M | |
Depreciation
| 9.84M | 10.11M | 9.21M | 8.66M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| - | - | -8.98% | -5.90% | - |
Gross Income
| - | (6.47M) | 104.10M | 99.64M | |
Gross Income Growth
| - | - | +1,710.19% | -4.28% | - |
Gross Profit Margin
| - | -177.17% | +91.88% | +92.00% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 158.15M | 156.26M | 172.10M | 210.04M | |
Research & Development
| 121.88M | 115.86M | 130.01M | 159.68M | |
Other SG&A
| 36.27M | 40.40M | 42.09M | 50.36M | |
SGA Growth
| -3.26% | -1.20% | +10.14% | +22.05% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | - | - |
EBIT after Unusual Expense
| (127.02M) | (162.72M) | (68.00M) | (110.40M) | |
Non Operating Income/Expense
| 4.57M | 1.58M | 9.81M | 13.40M | |
Non-Operating Interest Income
| 30.00K | 1.57M | 7.93M | 10.16M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (122.45M) | (161.14M) | (58.19M) | (97.01M) | |
Pretax Income Growth
| +18.77% | -31.60% | +63.89% | -66.71% | |
Pretax Margin
| -298.92% | -4,416.06% | -51.36% | -89.57% | |
Income Tax
| - | (204.00K) | 681.00K | (677.00K) | |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | (204.00K) | 681.00K | (677.00K) | |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (122.25M) | (161.82M) | (57.51M) | (97.01M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (122.25M) | (161.82M) | (57.51M) | (97.01M) | |
Net Income Growth
| +18.45% | -32.38% | +64.46% | -68.67% | |
Net Margin Growth
| -298.42% | -4,434.72% | -50.76% | -89.57% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (122.25M) | (161.82M) | (57.51M) | (97.01M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (122.25M) | (161.82M) | (57.51M) | (97.01M) | |
EPS (Basic)
| -2.3588 | -2.0521 | -0.5421 | -0.7015 | |
EPS (Basic) Growth
| +38.28% | +13.00% | +73.58% | -29.40% | |
Basic Shares Outstanding
| 51.83M | 78.86M | 106.10M | 138.28M | |
EPS (Diluted)
| -2.3588 | -2.0521 | -0.5421 | -0.7015 | |
EPS (Diluted) Growth
| +38.28% | +13.00% | +73.58% | -29.40% | |
Diluted Shares Outstanding
| 51.83M | 78.86M | 106.10M | 138.28M | |
EBITDA
| (117.18M) | (152.61M) | (58.79M) | (101.74M) | |
EBITDA Growth
| +18.28% | -30.23% | +61.48% | -73.06% | |
EBITDA Margin
| -286.06% | -4,182.13% | -51.89% | -93.94% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 21.154 | |
| Number of Ratings | 13 | Current Quarters Estimate | -0.258 | |
| FY Report Date | 06 / 2025 | Current Year's Estimate | -1.002 | |
| Last Quarter’s Earnings | -0.29 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.70 | Next Fiscal Year Estimate | -1.034 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 10 | 10 | 10 | 10 |
| Mean Estimate | -0.26 | -0.24 | -1.00 | -1.03 |
| High Estimates | -0.10 | -0.11 | -0.77 | -0.67 |
| Low Estimate | -0.30 | -0.31 | -1.13 | -1.26 |
| Coefficient of Variance | -22.96 | -26.13 | -11.40 | -16.29 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 12 | 12 | 10 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 1 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Wave Life Sciences - WVE
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Wave Life Sciences - WVE
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 24, 2025 | Christian O. Henry Director | 26,615 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $9.13 per share | 242,994.95 |
| Mar 24, 2025 | Christian O. Henry Director | 16,115 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $9.77 per share | 157,443.55 |
| Mar 24, 2025 | Christian O. Henry Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 6, 2025 | Chandra Vargeese See Remarks | 362,687 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $2.48 per share | 899,463.76 |
| Mar 6, 2025 | Chandra Vargeese See Remarks | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 6, 2025 | Chandra Vargeese See Remarks | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 7, 2025 | Paul B. Bolno President and CEO; Director | 338,351 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 7, 2025 | Paul B. Bolno President and CEO; Director | 1,000,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 7, 2025 | Christopher Francis See Remarks | 25,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 7, 2025 | Christopher Francis See Remarks | 151,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 7, 2025 | Kyle Moran Chief Financial Officer | 89,218 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 7, 2025 | Kyle Moran Chief Financial Officer | 252,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |